Back to top
more

InflaRx (IFRX)

(Real Time Quote from BATS)

$1.43 USD

1.43
116,643

+0.10 (7.52%)

Updated Apr 29, 2024 01:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

InflaRx (IFRX) delivered earnings and revenue surprises of -50% and 99.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing

by Zacks Equity Research

InflaRx N.V. (IFRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)

by Zacks Equity Research

InflaRx N.V. (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

InflaRx N.V. (IFRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why

by Zacks Equity Research

Shares of InflaRx (IFRX) show an upward trajectory after it obtained authorization for its first-ever marketed drug, which is approved for the treatment of critically ill COVID-19 patients.

Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More

by Zacks Equity Research

Regulatory updates from Fibrogen (FGEN) and Bristol Myers (BMY) are in focus in the biotech sector.

Biotech Stock Roundup: MRNA Provides Update, KALA, IFRX Surge on Regulatory News

by Zacks Equity Research

Regulatory and pipeline updates from Moderna (MRNA) and KALA are the key highlights for the biotech sector.

InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment

by Zacks Equity Research

InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.

Here's Why InflaRx N.V. (IFRX) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does InflaRx N.V. (IFRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

InflaRx N.V. (IFRX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

InflaRx N.V. (IFRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 10.81% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Are Options Traders Betting on a Big Move in InflaRx (IFRX) Stock?

by Zacks Equity Research

Investors need to pay close attention to InflaRx (IFRX) stock based on the movements in the options market lately.

InflaRx Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

InflaRx has been struggling lately, but the selling pressure may be coming to an end soon.

InflaRx (IFRX): Strong Industry, Solid Earnings Estimate Revisions

by Zacks Equity Research

InflaRx (IFRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

    The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, InflaRx, Legrand, Innate Pharma and DiaSorin

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, InflaRx, Legrand, Innate Pharma and DiaSorin

    Tirthankar Chakraborty headshot

    Europe Equities Are Hot on Stimulus Optimism: 5 Picks

    by Tirthankar Chakraborty

    Europe stocks rally on hopes that the European Union will unveil large stimulus package to reduce the economic fallout from the coronavirus pandemic.

    InflaRx Enters Oversold Territory

    by Zacks Equity Research

    InflaRx has been on a bit of a cold streak lately.

    InflaRx Enters Oversold Territory

    by Zacks Equity Research

    InflaRx N.V. (IFRX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

    InflaRx N.V. (IFRX) Reports Q1 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 30.65% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

    InflaRx (IFRX) Catches Eye: Stock Jumps 7.5%

    by Zacks Equity Research

    InflaRx (IFRX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.